Report overview
Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).
This report contains market size and forecasts of Malignant Mesothelioma Drugs in global, including the following market information:
Global Malignant Mesothelioma Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Malignant Mesothelioma Drugs Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Malignant Mesothelioma Drugs companies in 2021 (%)
The global Malignant Mesothelioma Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Pemetrexed Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Malignant Mesothelioma Drugs include AstraZeneca, Bristol-Myers Squibb, Roche, Merck, Novartis, Pfizer, Sanofi, Eli Lilly and Teva Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Malignant Mesothelioma Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Malignant Mesothelioma Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Malignant Mesothelioma Drugs Market Segment Percentages, by Type, 2021 (%)
Pemetrexed
Cisplatin
Carboplatin
Gemcitabine
Vinorelbine
Others
Global Malignant Mesothelioma Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Malignant Mesothelioma Drugs Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacies
Retail Pharmacies
Oncology Centers
Others
Global Malignant Mesothelioma Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Malignant Mesothelioma Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Malignant Mesothelioma Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Malignant Mesothelioma Drugs revenues share in global market, 2021 (%)
Key companies Malignant Mesothelioma Drugs sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Malignant Mesothelioma Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca
Bristol-Myers Squibb
Roche
Merck
Novartis
Pfizer
Sanofi
Eli Lilly
Teva Pharmaceuticals
Boehringer Ingelheim GmbH
Mylan
Fresenius Kabi
Sun Pharmaceuticals
Corden Pharma
Concordia International
Kyowa Hakko Kirin
Polaris Pharmaceuticals
MolMed
Ono Pharmaceutical
Nichi-Iko Pharmaceutical
